INBS
Intelligent Bio Solutions Inc.
There isn't enough reported data to score INBS yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
INBS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
INBS's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
INBS PE Valuation
INBS has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
INBS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect INBS's losses to grow, with revenue declining.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
INBS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$8.95 | +$7.55 |
| Q2 2026 | -$11.59 | +$8.41 |
| Q3 2023 | -$1,384.80 | -$84.71 |
| Q2 2023 | -$1,452.00 | -$103.91 |
| Q1 2023 | -$1,273.69 | -$92.14 |
| Q4 2022 | -$803.29 | +$810.26 |
| Q3 2022 | -$1,300.09 | +$313.46 |
INBS is still losing money, but far less than before: $8.95 per share over the past year, against $1,613.55 at its worst in late 2021.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over INBS on earnings quality, reporting a profit while its opponent remains loss making.
INBS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4M | +25% |
| Q2 2026 | $1.1M | +36% |
| Q1 2026 | $1.1M | +18% |
| Q4 2025 | $896.8K | +21% |
| Q3 2025 | $1.1M | +11% |
| Q2 2025 | $843.9K | +16% |
| Q1 2025 | $902.1K | +9.5% |
| Q4 2024 | $741.1K | -3% |
INBS has the edge over NVO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -193% | +77 points |
| Q2 2026 | -346% | +21 points |
| Q1 2026 | -278% | +5.2 points |
| Q4 2025 | -294% | +12 points |
| Q3 2025 | -270% | +3.2 points |
| Q2 2025 | -368% | +19 points |
| Q1 2025 | -283% | +76 points |
| Q4 2024 | -306% | -45 points |
INBS's operating margin was −193% last quarter, up 77 points from the same quarter a year ago, near the top of its range since 2020.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over INBS on profitability, with a higher operating margin.
INBS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$4.3M | -$1.6M |
| Q4 2025 | -$1.6M | +$689K |
| Q3 2025 | -$2.9M | -$530K |
| Q1 2025 | -$2.8M | -$308.8K |
| Q4 2024 | -$2.3M | +$544.4K |
| Q3 2024 | -$2.4M | -$1.1M |
| Q2 2024 | -$2.9M | -$2.4M |
| Q1 2024 | -$2.4M | +$71.9K |
NVO has the stronger cash trend. Its trailing FCF is down 14% versus its history, compared with INBS at down 50%.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
INBS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +94% | +1.5M shares |
| 1 year | +436% | +2.5M shares |
| 3 years | +50551% | +3.1M shares |
INBS has 3M diluted shares, up 436% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over INBS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
INBS Net Leverage
INBS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
INBS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.1 | Neutral |
| Stochastic | 25.1 | Neutral |
INBS's weekly RSI is 42 (neutral) and its Stochastic is 25 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
INBS PE vs Healthcare Sector
INBS has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
INBS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.71 | 13% above |
| 20 week MA | $1.98 | 2.5% below |
| 50 week MA | $3.82 | 49% below |
| 100 week MA | $9.38 | 79% below |
| 200 week MA | $95.8 | 98% below |
INBS has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 98% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
INBS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25,320.0 | $25,320.0 | 0% |
| 2021 | $25,320.0 | $3,864.0 | -85% |
| 2022 | $3,864.0 | $686.0 | -82% |
| 2023 | $686.0 | $40.6 | -94% |
| 2024 | $40.6 | $14.3 | -65% |
| 2025 | $14.3 | $4.84 | -66% |
| 2026 YTD | $4.84 | $1.93 | -60% |
INBS has finished every year since 2020 lower, and it's down 60% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over INBS on returns for 2026, with the stronger performance.